You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Mallinckrodt
Harvard Business School
Baxter
AstraZeneca

Last Updated: April 9, 2020

DrugPatentWatch Database Preview

Litigation Details for Takeda Pharmaceutical Company LTD. v. Teva Pharmaceuticals USA Inc. (D. Del. 2006)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Takeda Pharmaceutical Company LTD. v. Teva Pharmaceuticals USA Inc. (D. Del. 2006)

Docket   Start Trial Date Filed 2006-01-17
Court District Court, D. Delaware Date Terminated 2008-03-31
Cause 28:1338 Patent Infringement Assigned To Sue Lewis Robinson
Jury Demand None Referred To
Parties TAKEDA PHARMACEUTICAL COMPANY LTD.; TAP PHARMACEUTICAL PRODUCTS INC.; TEVA PHARMACEUTICAL INDUSTRIES LTD (ISRAEL); TEVA PHARMACEUTICALS USA INC.
Patents 4,255,431; 4,689,333; 5,013,743; 5,026,560; 5,093,132; 5,433,959; 6,749,864
Attorneys Arlene L. Chow; Arthur G. Connolly , III; Chad J. Peterman; Eric J. Lobenfeld; James Michael Lennon; James Walter Parrett , Jr.; John L. North; Karen Elizabeth Keller; Karen L. Pascale; Mary B. Graham; Philippe Y. Riesen; Richard de Bodo; Rodger Dallery Smith , II; Stuart E. Pollack; Tedd W. Van Buskirk; Willam F Cavanaugh
Firms Connolly, Bove, Lodge & Hutz; Womble Carlyle Sandridge and Rice PLLC
Link to Docket External link to docket
Small Molecule Drugs cited in Takeda Pharmaceutical Company LTD. v. Teva Pharmaceuticals USA Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Takeda Pharmaceutical Company LTD. v. Teva Pharmaceuticals USA Inc. (D. Del. 2006)

Date Filed Document No. Description Snippet Link To Document
2006-01-17 1 Exhibit E Pat. No. 4,()45,563, U.S. Pat. No. 4,255,431, Europ&m Patent Publication No. 45,?,£0, U.S. Pat No…Scllstedt et a§. .................... 514/533 4,255,431 3/193§ J§mggi‘cn et 211 514/338 4,563,…lillllllllillllil!lllll Usoos433 <_)A 1111 Patent Number: [45] Date of Patent: 5,433,959 * Jui. 18, 1995 9680602…Case 1:06-cv-00033-SLR Document 1-6 United States Patent m Makino et ai. {54] STABILIZED FHMWMICM CUMPOSFI…#39; T?'\P pm'rinn of the term nF §his; patent subsequent to Sep. 3, 2008 has been c§isclaimed External link to document
2007-04-04 106 Exhibit A - H those disclosed in U.S. Pat. No. 4,255,431 {Japnnese Uuexnmined Patent Laid-opeu No. 141733/79) and U.S…ofthe ‘098 patent, the ‘560 patent, the ‘321 patent, the ‘ 132 patent, and the ‘959 patent (coilectively…of the ‘098 patent, the ‘560 patent, the ‘32] patent, the ‘ 132 patent, and the ‘959 patent (coliectively… that the certificate extending the patent term of the ‘098 patent speaks for itself and Teva is Case…valid and enforceable claim of U.S. Patent No. 4,623,098 (“the ‘098 patent"). SECOND DEFENSE Teva has External link to document
2007-07-10 121 Amended Answer to Complaint and enforceable claim of U.S. Patent No. 5 ,026,560 (“the ‘5 60 patent”). THIRD DEFENSE Teva has not …of the ‘098 patent, the ‘560 patent, the ‘321 patent, the ‘ 132 patent, and the ‘959 patent (collectively… that the certificate extending the patent term of the ‘098 patent speaks for itself and Teva is Case… and enforceable claim of U.S. Patent No. 4,628,098 (“the ‘098 patent”). 10 Case 1:06-cv-00033-SLR … and enforceable claim of U.S. Patent No. 5 ,045 ,321 (“the ‘321 patent”). FOURTH DEFENSE Teva has not External link to document
2007-07-24 123 Answer to Counterclaim validity of certain claims of U.S. Patent Nos. 4,628,098, 5,026,560, 5,045,321, 5,093,132, and 5,433,959… (Non-Infringement of the ‘098 Patent) 6. Plaintiffs repeat and re-allege… (Non-Infringement of the ‘560 Patent) 8. Plaintiffs repeat and re-allege… (Non-Infringement of the ‘321 Patent) 10. Plaintiffs repeat and re-allege… (Non-Infringement of the ‘132 Patent) 12. Plaintiffs repeat and re-allege External link to document
2007-09-18 139 Exhibits 10 - 15 serial number 750,568 filed 1985, now U.S. Patent No. 4,689,333, does not contain the disclosure relied …rejection is the patentability of the claimed invention over Nohara et al. {U.S. ?atent No. 4,689,333), Rainer… 102/103 for one of the references, 4,689,333, . . \.D 4,689,333 is no longer relied upon. * * * §§ y…in view cf Ueno et al. (U.S. Patent No. 4,666,919) and Japanese Patent 19,'715/85. V. GROUPING…Filed 09/18/2007 Page 2 of 57 IN THE UNITED STATES PATENT AND TRAD£MARK OFFICE In re the Application of Tadashi External link to document
2007-10-08 146 Exhibits 5 (Part 2) through 12 U.S. Patent 4,255,431 03/10… U.S. Patent 4,255,431 File History 04/05… 959 Patents DTX436 U. S. Patent Application to Market…that the ‘098 patent was procured by inequitable conduct. In support of the patentability of the ‘098 …098 patent, Takeda submitted experimental data to the U.S. Patent and Trademark Office (“PTO”) from the External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Merck
Mallinckrodt
McKesson
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.